Acceptability and continuation of use of the subdermal contraceptive implant among adolescents and young women in Argentina: a retrospective cohort study.
Adolescence
adherence
pregnancy
public policy
satisfaction
subdermal implant
Journal
Sexual and reproductive health matters
ISSN: 2641-0397
Titre abrégé: Sex Reprod Health Matters
Pays: England
ID NLM: 101743493
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
medline:
14
4
2023
entrez:
12
4
2023
pubmed:
13
4
2023
Statut:
ppublish
Résumé
A new public policy was instituted in Argentina for free distribution of subdermal contraceptive implants to women aged 15-24 years old in the public healthcare system. The objective of this study is to determine the extent to which this population adhered to the implant, as well as predictors of continuation. The retrospective cohort study was based on a telephone survey of a random sample of 1101 Ministry of Health-registered implant users concerning the continuation of use, satisfaction with the method and side-effects, and reasons for removal. Descriptive statistics and multivariate regression analysis were used to explore the association between adherence and having received contraceptive counselling, satisfaction, and side effects. We found high levels of adherence (87%) and satisfaction (94%). Common reported side effects were amenorrhoea or infrequent bleeding, perceived weight gain, increased menstrual bleeding and headaches. Multivariate regression analysis indicates that, among adolescents, having received contraceptive counselling increased comfort, while frequent bleeding at six months hindered trust. Participants who had a history of a prior delivery or who had themselves primarily chosen the method were less likely to request the removal of the implant. Our results support the public policy of free implant distribution in the public health sector. This is a sustainable public policy that contributes to equity and access to effective contraception. It is appropriate for adolescents and young women and will also reduce unintended pregnancies. Our results suggest that counselling patients is key prior to insertion of the implant, as it improves acceptability and continuation.
Identifiants
pubmed: 37042700
doi: 10.1080/26410397.2023.2189507
pmc: PMC10101666
doi:
Substances chimiques
Levonorgestrel
5W7SIA7YZW
Contraceptive Agents, Female
0
Drug Implants
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2189507Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Références
N Engl J Med. 2017 Feb 2;376(5):461-468
pubmed: 28146650
Am J Obstet Gynecol. 2017 Apr;216(4):364.e1-364.e12
pubmed: 28038902
Contraception. 2014 Jun;89(6):578-83
pubmed: 24656553
Contraception. 2014 Nov;90(5):522-8
pubmed: 24973905
Clin Obstet Gynecol. 2014 Dec;57(4):635-43
pubmed: 25286295
Eur J Contracept Reprod Health Care. 2016 Jun;21(3):213-9
pubmed: 26848851
Fam Plann Perspect. 1996 Nov-Dec;28(6):256-60
pubmed: 8959415
Am J Obstet Gynecol. 2016 Jun;214(6):681-8
pubmed: 26875950
Obstet Gynecol. 2017 Nov;130(5):e251-e269
pubmed: 29064972
Hum Reprod. 2015 Nov;30(11):2527-38
pubmed: 26409014
Contraception. 2009 Dec;80(6):527-32
pubmed: 19913146
Lancet Glob Health. 2019 Feb;7(2):e227-e235
pubmed: 30683240
Perspect Sex Reprod Health. 2014 Sep;46(3):125-32
pubmed: 24961366
Hum Reprod Open. 2018 Jan 23;2018(1):hox030
pubmed: 30895242
Hum Reprod. 2014 Oct 10;29(10):2163-70
pubmed: 25085802
Int Perspect Sex Reprod Health. 2020 Dec 14;46(Suppl 1):35-43
pubmed: 33326398
Clin Ther. 1996 Jan-Feb;18(1):150-9
pubmed: 8851460
Matern Child Health J. 2017 Sep;21(9):1724-1733
pubmed: 27150948
Eur J Contracept Reprod Health Care. 2011 Jun;16(3):225-8
pubmed: 21395387
Hum Reprod. 2014 Jul;29(7):1393-9
pubmed: 24812309